TLR4 and COVID-19: Yet, the knowledge about immunological effects of OxPAPC remains controversial, as other studies have indicated that it may function as a TLR4 and TLR2 agonist both in vitro and in vivo, overall limiting its potential as drug to inhibit hyperinflammation in severe COVID-19 [19,[85], [86], [87], [88]].